Evidence map›Paper›PMID 41378341›Full record

ArticleResearch and practice in thrombosis and haemostasis2025

Rituximab-first versus eltrombopag monotherapy in pediatric persistent/chronic immune refractory thrombocytopenia after first-line therapy: a prospective multicenter cohort study.

Jingyao Ma, Zhifa Wang, Juntao Ouyang, Zheyan Lin, Lingling Fu, Zhenping Chen, Yan Liu, Lijuan Wang, Xi Lin, Xiaoling Cheng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jingyao MaHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zhifa WangHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Juntao OuyangHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zheyan LinHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Lingling FuHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zhenping ChenDepartment of Clinical Laboratory Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yan LiuHematology Department, Baoding Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Lijuan WangHematology Department, Henan Province Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Xi LinHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Xiaoling ChengDepartment of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yu HuHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Shuyue DongHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jinxi MengHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jie MaHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Runhui WuHematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune thrombocytopenia (ITP) in children is an autoimmune disorder in which a significant subset develops persistent or chronic disease requiring second-line therapies, yet the optimal sequencing of agents such as rituximab (RTX) and eltrombopag (ELT) to achieve sustained remission off-treatment remains (SRoT) undefined. Objectives: This study assessed whether RTX-first sequential therapy outperforms upfront ELT monotherapy in achieving durable remission for pediatric persistent/chronic ITP (p/cITP) after first-line failure. Methods: This nonrandomized multicenter prospective cohort study enrolled 55 children (April 2020 to July 2023) with refractory p/cITP until first-line therapy. They were assigned to RTX-first (RfG, Results: Among the 55 enrolled children (RfG = 35, EfG = 20), RfG had superior SRoT (30%; 95% CI, 15.6%-48.7%) than ELT-monotherapy group (0%; 95% CI, 0%-18.7%; Conclusions: RTX-first treatment yields a better SRoT and shorter TD than ELT monotherapy for pediatric p/cITP, with comparable remission and safety.

Indexed as

childreneltrombopagimmune thrombocytopenia (ITP)rituximabsecond-line therapy

Identifiers

PMID41378341
PMCPMC12686790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.